Retina/Vitreous News

Eyes with neovascular age-related macular degeneration that switched to faricimab generally had lower rates of lesion activity, longer treatment intervals and stable visual acuity.

Large language models may be helpful in generating scientific abstracts, according to research presented at the American Society of Retina Specialists annual meeting.

Pegcetacoplan may be a more effective treatment option than avacincaptad pegol for reducing geographic atrophy lesion growth in patients with age-related macular degeneration.

Undoubtedly, cost can be a barrier to optimal anti-VEGF treatment in the United States and around the world.

It has been nearly 3 years since the first ranibizumab biosimilar was approved for use in the U.S.

Most of us are familiar with the different classes of eye drops.

Opus Genetics received rare pediatric disease designation from the FDA for its ocular gene therapy designed to treat patients with a form of Leber congenital amaurosis, according to a press release.

A review found that OCT and visual acuity were among the most popular benchmarks in the management of diabetic macular edema in clinical practice guidelines.

In this video, Donald J. D’Amico, MD, discusses data from the phase 1/2 PRISM trial of 4D-150 in patients with neovascular age-related macular degeneration.

Patients with neovascular age-related macular degeneration who have responded poorly to anti-VEGF monotherapy may require an average of nine injections of faricimab before improvement is seen.